Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis

Yang, Xue-Qin; Li, Chong-Yi; Xu, Ming-Fang; Zhao, Hong; Wang, Dong

doi:10.1186/s12885-015-1978-2

Table 1 Summary of studies

From: Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis

Author	Phase	Race	Jadad score	Group	Regimen	N	Eligible for evaluation	Male (%)	Median age	PS 0-1(%)	Stage IV(%)	Histology Ad. (%)	Median cycles
Negoro S et al.[13] 2003	III	Japanese	5	IP	P: 80mg/m² day 1, I: 60mg/m², day 1, 8, 15, q 28days	133	129	76	64	94	62	60	3
Negoro S et al.[13] 2003	III	Japanese	5	PV	P: 80mg/m² d1, V: 3mg/m², day 1, 8, 15, q 28days	133	122	80	64	94	63	60	2
Yamamoto N et al.[14] 2004	II	Japanese	5	DI	D: 60mg/m² day 8, I: 60mg/m², day 1, 8, q 21days	57	57	67	60	100	75	77	2
Yamamoto N et al.[14] 2004	II	Japanese	5	DP	P: 80mg/m² day 1, D: 60mg/m², day 1, q 21days	51	51	73	62	100	78	71	2
Ohe Y et al.[15] 2007	III	Japanese	5	IP	P: 80mg/m² day 1, I: 60mg/m², day 1, 8, 15, q 28days	151	145	67	62	100	79	83	3
				TC	T: 200mg/m² day 1, C: AUC 6, day 1, q 21days	150	145	68	63	100	81	72	3
				GP	P: 80mg/m² day 1, G: 1000mg/m², day 1, 8, q 21days	151	146	70	61	100	79	74	3
				NP	P: 80mg/m² day 1, N :20mg/m² , day 1, 8, q 21days	150	145	70	61	100	82	75	3
Han JY et al.[16] 2008	II	Korean	5	IP	P: 30mg/m², I :65mg/m², day 1, 8, q21days	75	72	77	58	89	87	71	5
Han JY et al.[16] 2008	II	Korean	5	GN	G: 900mg/m², N :25mg/m² , day 1, 8, q 21days	71	71	82	60	92	87	69	4
Zhao WY et al.[17] 2012	II	Chinese	4	IP	P: 25mg/m² day 1–3, I :100mg/m², day 1, 8, q 21days	31	31	68	59*	68	65	61	3
Zhao WY et al.[17] 2012	II	Chinese	4	GP	P: 25mg/m² day 1–3, G :1000mg/m², day 1, 8, q 21days	32	32	72	60*	75	59	56	3
Takiguchi Y et al.[18] 2000	III	Japanese	3	IP	P: 80mg/m² day 1, I: 60mg/m² , day 1, 8, 15, q 28days	104	98	75	62	94	59	NR	NR
Takiguchi Y et al.[18] 2000	III	Japanese	3	PV	P: 80mg/m² day 1, V: 3mg/m² , day 1, 8, 15, q 28days	106	101	75	62	94	59	NR	NR
Rocha Lima CM et al.[19] 2004	II	American	5	GI	G :1000 mg/ m² day 1, 8, I: 100 mg/m², day 1, q 21 days	39	36	72	63	100	77	46	4
Rocha Lima CM et al.[19] 2004	II	American	5	GD	G: 1000mg/m² day 1, 8, D: 40mg/m², day 1,8, q 21days	39	36	46	57	100	79	59	4

I Irinotecan, P cisplatin, V vindesine, G gemcitabine, N navelbine, D docetaxel, T paclitaxel, C carboplatin, NR not reported, Ad. adenocarcinoma
* This is mean data, not median data.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us